Theme: Translational Research

Invited Speakers on the Theme of Translational Research

Symposium – Neuroendocrine Therapeutics: What’s the Latest?

Dr. Jean BOUTIN, Institut de Recherches Internationales Servier, France

Jean A. Boutin graduated (Thèse d’Etat ès Sciences Biologiques) from the Université de Nancy (France) on drug metabolism (UGT). He did two postdoctoral training periods at Johns Hopkins University School of Medicine (Baltimore) and at the Karolinska Institutet (Stockholm, Sweden). He was hired as protein chemist in Les Laboratoires SERVIER (LLS) in 1986. During the 30ish last years, Dr. Boutin moved from oncology to peptide research and then molecular & cellular pharmacology. Recently, LLS created a drug discovery platform that Dr. Boutin led until October, 1st, 2016. Since then, he is Directeur de la Prospective particularly in the technological areas associated with molecular pharmacology. These areas include, but are not limited to drug molecular modeling, ligand/protein biophysical interaction measurements, protein chemistry, stem cells, structural biology, chemogenetics, HTS, biologics…The main interests of Dr. Boutin are N-myristoyltransferase, melatonin, quinone reductase 2, MCH and autotaxin. He published about 250 scientific papers and book chapters.

Dr. Waljit DHILLO, Imperial College London, UK

 Clinical Studies with Kisspeptin

Waljit Dhillo is Professor of Endocrinology & Metabolism and Consultant Endocrinologist at Imperial College London. He completed his medical training at St Bartholomew’s Hospital Medical School, University of London. During this time he completed an Intercalated BSc (First Class Honours) in Biochemistry funded by the Medical Research Council. Subsequently during his clinical training he completed a PhD as a Wellcome Trust Clinical Training Fellow at Imperial College. He was subsequently awarded 3 National Institute for Health Research (NIHR) personal Fellowships – Clinician Scientist Fellowship 2004-2009, Career Development Fellowship 2009-2015 and most recently a Research Professorship 2015-2020. He was appointed to a personal Chair at Imperial College in 2011. He has published 156 articles and a h-index of 36 (Web of Science).

 Dr. Paul Emmerson, Eli Lilly and Company, Indianapolis, IN, USA

The role of GDF15 and its receptor GFRAL in the regulation of food intake and body weight

Paul Emmerson is currently a Research Advisor in the Diabetes, Incretin Discovery Group at Eli Lilly and Company. He received his doctorate in pharmacology from the University of Michigan and completed a National Institute on Drug Abuse supported post-doctoral fellowship in Dr. Richard Miller’s laboratory at The University of Chicago where he studied the function of orexigenic neuropeptides in the hypothalamus. He joined Eli Lilly in 2000 where his group has been focused on the discovery of novel therapeutics for obesity and type 2 diabetes through targeting peptide and protein receptors in the hypothalamus and brain stem involved in the regulation of food intake and body weight.

Dr. Matthias TSCHÖP, Helmholtz Zentrum Muenchen, Germany

Readjusting Gut-Brain Signalling with Unimolecular Polyagonists: Translational Potential

Professor Matthias H. Tschöp received his M.D. from Ludwig-Maximilian University of Munich, where he also trained as a physician in internal medicine. In 1998 he accepted an invitation for a postdoctoral fellowship at the Eli Lilly Research Laboratories in Indianapolis, USA, before returning to Europe in 2002 to establish his independent research laboratory at the German Institute of Human Nutrition (DIfE) in Potsdam. He later returned to the United States where he joined the University of Cincinnati to ultimately serve as the Director of the Diabetes and Obesity Center of Excellence and Arthur Russell Morgan Endowed Chair of Medicine. In 2011, Professor Tschöp accepted the position of Scientific Director of the Helmholtz Diabetes Center at Helmholtz Center Munich and was named Chair of the Division of Metabolic Diseases at Technical University of Munich. Professor Tschöp is the first German physician to receive the prestigious Alexander von Humboldt Professorship (2012). He was elected into the German National Academy of Science (Leopoldina) in 2013 and in 2012 was named adjunct Professor at Yale University, USA. He started the peer-reviewed open access journal Molecular Metabolism, which he leads as the Editor-in-Chief (2016 impact factor: 6.8). In 2016, Matthias Tschöp received an honorary doctorate of the University of Leipzig and was named Director for Biomedicine of the Helmholtz Pioneer Campus in Munich, which he co-founded.

Dr. Michael TROWER, KaNDy Therapeutics Ltd, UK

Reducing the Heat with Neurokinin Antagonism; A New Non-Hormonal Approach for Treating Hot Flashes

Mike Trower is Chief Scientific Officer of KaNDy Therapeutics a company dedicated to developing breakthrough treatments for debilitating Women’s Health conditions. He has more than 25 years’ drug discovery and development experience in the pharmaceutical and biotechnology industries. Prior to KaNDy, Mike worked at GlaxoSmithKline, where he was Head of the External Drug Discovery Group in the Neurosciences Division.  He has broad expert knowledge of neurokinin receptor system biology and in particular how it relates to KNDy neuronal activity.  Mike has a BSc (Hons) and a PhD in biological sciences and held post-doctoral positions in DuPont Inc. in Delaware, US and the Medical Research Council in Cambridge, UK under the Nobel laureate Professor Sydney Brenner.

 

Dr. Scott STRUTHERS, Crinetics Pharmaceutical Inc, USA

Suppression of GH and IGF1 in Healthy Volunteers by a Novel, Non-Peptide Orally Available Somatostatin Receptor Against CRN00808

Dr. Struthers is a Founder and CEO of Crinetics Pharmaceuticals, Inc. discovering and developing novel therapeutics for the treatment of endocrine diseases and related cancers.  Prior to founding Crinetics, he was Senior Director and Head, Endocrinology and Metabolism at Neurocrine Biosciences where he initiated and led the company’s efforts to discover and develop orally active, nonpeptide GnRH antagonists. This resulted in a first-in-class compound, elagolix, that has demonstrated safety and efficacy in over 40 clinical trials totaling more than 3,000 patients with endometriosis and uterine fibroids. Dr. Struthers received his Ph.D. in Physiology and Pharmacology from the University of California, San Diego, under the guidance of Professor Wylie Vale at the Salk Institute for Biological Studies where his doctoral research focused on somatotroph development and regulation. He is an author of more than 75 scientific publications in the fields of computational and medicinal chemistry, endocrinology, receptor biology and clinical pharmacology.

Follow ICN 2018:

Facebook https://twitter.com/ICN_2018" target="_blank">Twitter YouTube

CONFERENCE NEWSLETTER

Switch to desktop version

Conference Newsletter

Close

Subscribe to the Newsletter to receive important information about the upcoming Conference.